<DOC>
	<DOCNO>NCT00957268</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetic safety profile alogliptin child , adolescent , adult type 2 diabetes mellitus .</brief_summary>
	<brief_title>Pharmacokinetics , Pharmacodynamics , Safety Alogliptin Children , Adolescents Adults With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Alogliptin selective , orally available inhibitor dipeptidyl peptidase-4 developed Takeda Global Research &amp; Development treatment type 2 diabetes mellitus . Inhibition dipeptidyl peptidase-4 ( DPP-4 ) prolong action 2 important incretin hormone , glucagon-like peptide-1 ( GLP-1 ) glucose-dependent insulinotropic peptide ( GIP ) . These hormone responsible increase insulin synthesis , regulate β-cell proliferation , inhibit gastric emptying , inhibit glucagon secretion . To date , alogliptin study participant less 18 year age . As adult , grow evidence increase prevalence type 2 diabetes mellitus child adolescent . This study design determine pharmacokinetic , pharmacodynamic , safety profile alogliptin child adolescent type 2 diabetes mellitus . These profile compare similarly match adult participant type 2 diabetes mellitus . Pharmacokinetic , pharmacodynamics , safety endpoint analyze .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>Inclusion criterion child adolescent participant ( Groups 1 2 , respectively ) : 1 . Participant male female 10 17 year age . 2 . Participant parent legal guardian capable understand comply protocol requirement . 3 . Participant capable understanding inform consent form ( ICF ) assent participate . The parent legal guardian participant must able understand sign ICF prior initiation study procedure . 4 . Participant weigh least 36 kg ( 79 pound ) Screening body mass index ( BMI ) least 18 kg/m^2 . 5 . Participants diagnosis type 2 diabetes mellitus ( T2DM ) ( noninsulin dependent ) base diagnostic criterion American Diabetes Association ( ADA ) . Criteria include : 1 . Fasting plasma glucose level ≥ 126 mg/dL fast define caloric intake least 8 hour , 2 . 2hour plasma glucose level ≥ 200 mg/dL oral glucose tolerance test , 3. random plasma glucose level ≥ 200 mg/dL , 4. glycated hemoglobin ( HbA1c ) ≥ 6.5 % . 6 . Diagnosis could historical ( document ) , participant could diagnose study . 7 . Participants fast serum Cpeptide concentration ≥ 0.8 ng/mL ( ≥ 0.26 nmol/L ) Screening Visit . 8 . Participants may take concomitant metformin dose stable least 30 day prior Day 1 ( day first dose ) . Inclusion criterion adult participant ( Group 3 ) : 9 . Participant male female , 18 65 year age , inclusive gender race match adult participant T2DM . 10 . Participant capable understand comply protocol requirement willing sign ICF prior initiation study procedure gender race match adult participant T2DM . 11 . Participant weigh least 50 kg ( 110 pound ) Screening BMI 23 kg/m^2 45 kg/m^2 ( except Asian Asiandescendant participant range 20 kg/m^2 35 kg/m^2 ) , inclusive gender race match T2DM adult participant . 12 . Participants diagnosis T2DM ( noninsulin dependent ) base diagnostic criterion ADA . Criteria include : 1 . Fasting plasma glucose level ≥ 126 mg/dL fast define caloric intake least 8 hour , 2 . 2hour plasma glucose level ≥ 200 mg/dL oral glucose tolerance test , 3. random plasma glucose level ≥ 200 mg/dL , 4 . HbA1c ≥ 6.5 % . 13 . Diagnosis could historical ( document ) participant could diagnose study . 14 . Participants may take concomitant metformin dose stable least 30 day prior Day 1 . 15 . Participants may take statin antihypertensive drug dose stable least 30 day prior Day 1 . Inclusion criterion participant ( Groups 1 , 2 , 3 ) : 16 . Female participant childbearing potential male participant sexually active agree routinely use adequate contraception Screening 30 day receive dose study drug . NOTE : Women childbearing potential define surgically sterilize ( hysterectomy , bilateral oophorectomy , tubal ligation ) postmenopausal ( define least 45 year age 1 year since last regular menses ) . 17 . Participant negative urine test result select substance abuse ( include alcohol cotinine ) Screening Checkin ( Day 1 ) . 18 . Participant clinical chemistry , hematology , complete urinalysis ( fast least 8 hour ) result within reference range test laboratory ( except result associated T2DM ) unless outofrange result deem clinically meaningful investigator sponsor . 19 . Participant negative test result hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( antiHCV ) , know history human immunodeficiency virus . 1 . Participant currently participate another investigational study take investigational drug within 30 day prior Day 1 . 2 . Participant receive alogliptin previously . 3 . Participant study site employee , immediate family member ( ie , spouse , parent , child , sibling ) study site employee involve conduct study . 4 . Participant receive donated blood blood product within 30 day prior Screening plan donate blood study . 5 . Participant know hypersensitivity alogliptin related compound . 6 . Participant history drug abuse ( define illicit drug use ) history alcohol abuse ( define consumption 4 alcoholic drink per day ) within 1 year prior study Day 1 . 7 . Participant acute , clinically significant illness ( exclude T2DM ) within 30 day prior study Day 1 . 8 . Participant condition prior therapy , opinion investigator , would make participant unsuitable study . 9 . Participant history clinical manifestation significant metabolic ( exclude T2DM ) , hematologic , pulmonary , cardiovascular , gastrointestinal , neurologic , hepatic , renal , urologic , immunologic , musculoskeletal , psychiatric disorder . 10 . Participant hemoglobin value &lt; 12 g/dL . 11 . Participant systolic blood pressure &gt; 140 mm Hg diastolic blood pressure &gt; 90 mmHg Screening Checkin ( Day 1 ) . 12 . Adult participant alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level great 2 time upper limit normal ( ULN ) , active liver disease , jaundice Screening Visit Checkin ( Day 1 ) . 13 . Pediatric participant ALT AST level great 1.5 time ULN Screening Visit Checkin ( Day 1 ) . 14 . Participant serum creatinine level &gt; 1.5 mg/dL . 15 . Participant creatinine clearance ( CrCl ) &lt; 50 mL/min ( normalize body surface area 1.73 m^2 ) . 16 . Participant history abdominal surgery ( except laparoscopic cholecystectomy uncomplicated appendectomy ) thoracic nonperipheral vascular surgery within 6 month prior Day 1 . 17 . Participant history presence clinically significant abnormal 12lead electrocardiogram ( ECG ) result determine investigator Takeda Screening Checkin ( Day 1 ) . 18 . Participant history cancer , basal cell carcinoma Stage I squamous cell carcinoma skin remission least 5 year prior first dose study drug . 19 . If female , participant pregnant lactate intend become pregnant , , within 30 day receive study drug . 20 . If male , participant intend impregnate others study 30 day receive study drug . 21 . Participant consume unable abstain consumption product contain alcohol , caffeine , xanthine , food beverage contain grapefruit juice Sevilletype oranges within 72 hour prior study Day 1 duration study . 22 . Participant use tobacco ( ie , nicotine ) product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine gum ) within 6 week prior study Day 1 , unwilling abstain product duration study . 23 . Participant use nutraceutical preparation within 28 day prior study Day 1 . 24 . Participant currently take ketoconazole , fluconazole , gemfibrozil , rifampin , carbamazepine take within 28 day prior Checkin ( Day 1 ) . 25 . Participant poor peripheral venous access . 26 . Participant medical history clinical laboratory evidence indicate diagnosis type 1 diabetes secondary form diabetes , include maturityonset diabetes young ( MODY ) .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Non-insulin dependent diabetes mellitus</keyword>
	<keyword>Drug therapy</keyword>
	<keyword>Pediatrics</keyword>
</DOC>